Clinical trial Recruiting at 1 site Observational Ages 18 to 80

Research on primary aldosteronism and its effects on hypertension

Official title: Chongqing Primary Aldosteronism Study

Run by Chongqing Medical University · NCT03224312 · Data updated 2026-11-12

This study is trying to understand how primary aldosteronism affects high blood pressure over time by looking at a large group of patients and collecting samples to find better ways to manage the condition.

Quick facts

Study typeObservational
Ages18 Years to 80 Years
SexAll
Enrollment1500 (estimated)
SponsorChongqing Medical University
Academic / other
Locations1 site (Chongqing, Chongqing Municipality)
StatusRecruiting
StartedOctober 1, 2016
Main results expectedDecember 31, 2027
Study endsDecember 31, 2028
Registry record updatedSeptember 6, 2023
Trial IDNCT03224312 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are hypertensive patients who have completed aldosterone-renin ratio screening and are willing to provide informed consent.

Probably not a fit

Patients with severe cardiac, hepatic, or renal dysfunction, or those with other types of secondary hypertension, will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to establish a large cohort of patients with primary aldosteronism (PA) and essential hypertension, focusing on long-term follow-up of cardiovascular and renal outcomes. It will collect extensive biological samples, including blood, urine, and adrenal tissue, to create a comprehensive database for genomics, metabonomics, and proteomics analysis. The goal is to explore the mechanisms behind PA, identify risk factors, and develop diagnostic methods and biomarkers for better management of the condition.

Why it matters

Potential benefit: If successful, this research could lead to improved understanding and management of primary aldosteronism, potentially reducing cardiovascular and renal complications in affected patients.

How similar studies have gone: While this study builds on existing research in hypertension, its specific focus on primary aldosteronism and comprehensive biological analysis may offer novel insights.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. hypertensive patients who completed ARR screening and necessary further tests;
2. Voluntary to sign the informed consent.

Exclusion Criteria:

1. patients with severe cardiac, hepatic or renal dysfunction;
2. suspicious or confirmed other types of secondary hypertension, including Cushing's syndrome, pheochromocytoma and renal artery stenosis et al.

Where it's running

  • Qifu Li
    Chongqing, Chongqing Municipality, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.